What is the first step for drug approval in the UAE?

The mandatory first step is federal registration through the Ministry of Health and Prevention (MOHAP). You cannot legally import or market a pharmaceutical product anywhere in the UAE without initial MOHAP approval.

Why do I need separate approval from DOH if MOHAP already approved my drug?

MOHAP grants federal marketing authorization and sets the public price. However, the Department of Health (DOH) in Abu Dhabi controls its own massive healthcare network (SEHA) and mandates its own formulary inclusion processes, separate health technology assessments (HTA), and specific reimbursement criteria for its insured population.

How are pharmaceutical prices determined in the UAE?

MOHAP determines the exact CIF (Cost, Insurance, and Freight) and Public price. They utilize an International Reference Pricing (IRP) basket of around 36 countries, combined with the country of origin's price, adopting the lowest available authorized price.

Is health insurance mandatory across the UAE?

Health insurance is completely mandatory in Abu Dhabi (regulated by DOH) and Dubai (regulated by DHA). The Northern Emirates are currently transitioning toward comprehensive mandatory coverage models. This high penetration of private and semi-private insurance makes formulary access critical.

How can market research help with UAE market access?

Our market access research maps the precise evidentiary requirements of DOH and DHA formulary committees. By conducting IDIs with key decision-makers and payers, we identify value drivers—such as reduced hospitalization rates or localized cost-effectiveness models—that will accelerate your drug's inclusion in Tier 1 formularies.

Market Access Strategy for Pharma in the UAE: DOH vs MOHA...

The Tripartite Regulatory System

Market Access in the UAE is not monolithic. Pharmaceutical companies must navigate a highly structured, tripartite regulatory and payer environment. True market access means achieving 1) Federal regulatory approval, 2) Emirate-level formulary inclusion, and 3) Favorable reimbursement status across a heavily insured population.

MOHAP: The Federal Gateway

The Ministry of Health and Prevention (MOHAP) is the overarching federal regulatory authority. All pharmaceutical products, medical devices, and supplements must be registered here first.

The Process: Extremely rigorous, utilizing eCTD submissions. MOHAP emphasizes safety, efficacy, and quality.
Fast-Track Pathways: MOHAP offers accelerated registration for innovative breakthrough therapies, orphan drugs, or molecules already approved by strict regulatory authorities like the FDA or EMA. This can reduce review timelines significantly.
Pricing Authority: MOHAP holds the singular authority to establish the official Public Price across the entire UAE federation, leveraging a strict International Reference Pricing (IRP) mechanism.

Department of Health (DOH) Abu Dhabi: The Value Assessor

Abu Dhabi's healthcare system is highly advanced, data-driven, and governed by the Department of Health (DOH). Success in Abu Dhabi requires moving beyond simple safety/efficacy to proving quantifiable health economic value.

Formulary Access: DOH manages the process for getting drugs onto the approved formularies for the massive SEHA network (Abu Dhabi Health Services Company) and mandatory insurance schemes (Thiqa for nationals, basic/enhanced plans for expats).
Data Requirements: DOH increasingly demands robust Health Technology Assessments (HTA), pharmacoeconomic modeling, and budget impact analyses tailored specifically to the UAE demographic.

Dubai Health Authority (DHA): The Competitive Hub

Dubai's healthcare landscape, regulated by the Dubai Health Authority (DHA), is characterized by a sprawling, highly competitive private sector.

Insurance Landscape: Under Dubai's mandatory health insurance law, the population is covered by a myriad of private insurers (e.g., Daman, Nextcare, Oman Insurance).
Access Strategy: Market access here is dual-pronged: ensuring inclusion in the DHA's public hospital formularies (like Rashid Hospital) while aggressively negotiating with prominent private hospital groups (Mediclinic, Aster, NMC) and major Third-Party Administrators (TPAs) to reduce patient co-pays and secure preferred-tier placement.

Pricing and the Insurance Landscape

The UAE boasts near-universal health coverage, but the depth of coverage varies drastically by tier (VIP plans vs. Basic packages). Because MOHAP fixes the maximum public price, manufacturers cannot compete on arbitrary price drops. Instead, companies compete via:

Patient Support Programs (PSPs): Offering compliance support or co-pay assistance (where legally permissible) to drive volume.
Value-Based Agreements: Innovative contracting linking payment directly to clinical outcomes is slowly gaining traction, particularly for high-cost oncology and rare disease gene therapies.

Strategic Recommendations from BioNixus

To succeed simultaneously in Abu Dhabi and Dubai, pharmaceutical companies must base their submissions on localized evidence. BioNixus conducts targeted Market Access research—including deep-dive interviews with P&T (Pharmacy and Therapeutics) committee members and insurance medical directors—to construct compelling, locally relevant value dossiers that satisfy the distinct demands of both DOH and DHA.